Mark Jeffrey DeLong, Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 19,826 shares at $56.90 ($1.1M) on 2024-03-18, disclosed to the SEC on 2024-03-19.
Open-market sale of $1.1M APLS by Chief Business & Strat Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.90 | 9,913 | $564K | 50.0% |
| 2 | $56.90 | 9,913 | $564K | 50.0% |
| Total | $56.90 avg | 19,826 | $1.1M | 100% |
| Filing → |
| APLS | SELL | 2026-01-21 | $26K | — | Filing → |
| APLS | SELL | 2026-01-15 | $39K | — | Filing → |
| APLS | SELL | 2025-02-12 | $10K | — | Filing → |